Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128940) titled 'Lisaftoclax (A Novel BCL2 Inhibitor) Combined with Daunorubicin and Cytarabine in the Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients: A Clinical Study' on July 28.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: West China Hospital of Sichuan University

Condition: Acute Myeloid Leukemia

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-07-28

Target Sample Size: Treatment Group:43;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=335099

Published by HT Digital Content Services with p...